Hospital
Chippenham & Johnston-Willis Hospitals INC
Chippenham & Johnston-Willis Hospitals INC was paid $103.74M by Medicaid between Jan 2018 and Dec 2024, across 395 billing codes. Its largest line is 99283, emergency room visit (moderate) — 30% of everything it billed.
33Billing provider infoCHIPPENHAM & JOHNSTON-WILLIS HOSPITALS INC
RICHMOND, VA 23225
RICHMOND, VA 23225
33aNPI1598708513assigned 06/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$103.74M
24GClaims2,512,798
24DCodes billed395
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#2 of 80
Median peer was paid$14.69M
This provider vs. median7.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 281,757 | $7.39M | |
| 2019 | 383,211 | $11.42M | |
| 2020 | 337,580 | $12.75M | |
| 2021 | 384,692 | $15.52M | |
| 2022 | 388,176 | $17.72M | |
| 2023 | 410,593 | $20.49M | |
| 2024incomplete | 326,789 | $18.45M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 30% | 178,512 | 152,378 | $30.71M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 100,125 | 83,799 | $15.89M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.8% | 41,961 | 37,490 | $7.06M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.8% | 22,558 | 19,803 | $3.90M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.7% | 22,006 | 19,460 | $3.81M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 23,176 | 20,242 | $3.68M |
| G0378 | Hospital observation service, per hour | 3.3% | 31,384 | 15,847 | $3.44M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.4% | 10,767 | 9,706 | $2.47M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.2% | 12,677 | 11,702 | $2.24M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 4,326 | 3,924 | $2.10M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 4,815 | 4,252 | $1.30M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.1% | 1,603 | 1,468 | $1.11M |
383 more codes
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12,376 | $1000K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 6,062 | $994K |
| 76818 | <1% | 13,055 | $894K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 21,836 | $893K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,629 | $871K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,545 | $832K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 16,848 | $680K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 27,331 | $663K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,279 | $659K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,843 | $609K |
| 97163 | <1% | 4,814 | $446K | |
| 12001 | <1% | 1,960 | $430K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 5,027 | $426K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 11,791 | $410K |
| 12011 | <1% | 1,815 | $406K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,602 | $393K |
| 97597 | <1% | 3,577 | $385K | |
| 93458 | <1% | 257 | $384K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 12,290 | $378K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,257 | $373K |
| 76830 | Ultrasound, transvaginal | <1% | 4,926 | $354K |
| 76801 | <1% | 7,048 | $344K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 556 | $337K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,391 | $314K |
| 19318 | <1% | 30 | $306K | |
| 15002 | <1% | 427 | $302K | |
| 10060 | <1% | 2,192 | $301K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,648 | $301K |
| 97602 | <1% | 1,434 | $261K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,579 | $255K |
| 76642 | <1% | 2,042 | $252K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,197 | $251K |
| 80053 | Comprehensive metabolic panel | <1% | 80,173 | $251K |
| 93971 | <1% | 2,821 | $244K | |
| 59025 | Fetal non-stress test | <1% | 1,461 | $234K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 270 | $234K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 56,245 | $230K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 8,523 | $230K |
| 58661 | <1% | 85 | $230K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 68,359 | $191K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,384 | $187K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 8,444 | $186K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,468 | $183K |
| 47562 | <1% | 59 | $183K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,077 | $181K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 285 | $176K |
| 97161 | <1% | 1,359 | $169K | |
| 70491 | <1% | 1,064 | $163K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,062 | $163K |
| 76820 | <1% | 3,034 | $155K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,421 | $154K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 702 | $152K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 29,438 | $150K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 67,748 | $146K |
| 74174 | <1% | 650 | $140K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 5,208 | $138K |
| 70498 | <1% | 823 | $130K | |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 491 | $127K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,047 | $124K |
| 97016 | <1% | 5,796 | $123K | |
| 71250 | <1% | 1,980 | $122K | |
| 85027 | <1% | 147,571 | $121K | |
| 83880 | <1% | 15,104 | $119K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 139 | $117K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,126 | $115K |
| 12002 | <1% | 558 | $110K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,761 | $109K |
| 36430 | <1% | 684 | $106K | |
| 97162 | <1% | 1,105 | $102K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 150 | $100K |
| 76770 | <1% | 980 | $99K | |
| 93798 | <1% | 1,286 | $98K | |
| 72141 | <1% | 625 | $97K | |
| 97167 | <1% | 2,254 | $94K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,629 | $93K |
| 70486 | <1% | 2,506 | $93K | |
| 71045 | Radiologic examination, chest; single view | <1% | 34,617 | $92K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,801 | $89K |
| 70496 | <1% | 461 | $88K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 619 | $88K |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 1,171 | $83K |
| 97116 | <1% | 2,705 | $83K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 322 | $82K |
| 93970 | <1% | 745 | $81K | |
| 72131 | <1% | 1,880 | $81K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 622 | $79K |
| 95816 | <1% | 401 | $76K | |
| 87040 | <1% | 9,943 | $75K | |
| 76870 | <1% | 939 | $73K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,749 | $72K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,675 | $72K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,714 | $65K |
| 84484 | <1% | 47,322 | $65K | |
| 76536 | <1% | 609 | $64K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 655 | $62K |
| 90715 | <1% | 3,633 | $61K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 499 | $61K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,484 | $60K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 49 | $58K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,813 | $55K |
| 94660 | <1% | 266 | $55K | |
| 29125 | <1% | 369 | $55K | |
| 93017 | <1% | 459 | $52K | |
| 74018 | <1% | 5,384 | $51K | |
| 97166 | <1% | 888 | $50K | |
| 80076 | <1% | 19,331 | $49K | |
| 77336 | <1% | 592 | $47K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,169 | $44K |
| 85379 | <1% | 11,976 | $44K | |
| 76937 | <1% | 1,180 | $43K | |
| 73610 | <1% | 6,104 | $40K | |
| 93325 | <1% | 220 | $38K | |
| 77412 | <1% | 98 | $34K | |
| 73030 | <1% | 5,220 | $31K | |
| 77300 | <1% | 316 | $31K | |
| 80051 | <1% | 13,314 | $31K | |
| 88307 | <1% | 1,823 | $26K | |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 337 | $26K |
| 15004 | <1% | 30 | $26K | |
| 92610 | <1% | 445 | $26K | |
| 73560 | <1% | 1,860 | $25K | |
| 83605 | <1% | 15,249 | $24K | |
| C1776 | Joint device (implantable) | <1% | 224 | $24K |
| 73564 | <1% | 6,153 | $24K | |
| 76813 | <1% | 342 | $24K | |
| 73110 | <1% | 3,666 | $23K | |
| 58558 | <1% | 15 | $22K | |
| 83735 | <1% | 40,658 | $21K | |
| 76825 | <1% | 146 | $20K | |
| 86850 | <1% | 10,762 | $20K | |
| 73630 | <1% | 5,846 | $20K | |
| 93308 | <1% | 60 | $19K | |
| 76821 | <1% | 733 | $19K | |
| 73590 | <1% | 3,148 | $18K | |
| 72110 | <1% | 2,251 | $18K | |
| 73502 | <1% | 2,568 | $18K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,987 | $17K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 42,829 | $16K |
| 77066 | Tomosynthesis, mammo | <1% | 870 | $16K |
| 77334 | <1% | 135 | $16K | |
| 73552 | <1% | 1,356 | $16K | |
| 77295 | <1% | 39 | $15K | |
| 73130 | <1% | 5,027 | $15K | |
| 73080 | <1% | 2,198 | $15K | |
| 87486 | <1% | 1,010 | $14K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 12,923 | $14K |
| 82565 | <1% | 17,856 | $14K | |
| 72100 | <1% | 1,841 | $14K | |
| 81001 | <1% | 62,599 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,758 | $13K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 20,814 | $13K |
| 84702 | <1% | 13,034 | $13K | |
| 86923 | <1% | 493 | $12K | |
| 86900 | <1% | 12,388 | $12K | |
| 73090 | <1% | 2,196 | $12K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 35,066 | $11K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 290 | $11K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 39,093 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,801 | $11K |
| 83690 | <1% | 38,408 | $11K | |
| 85610 | <1% | 23,482 | $11K | |
| 88304 | <1% | 2,054 | $10K | |
| 64415 | <1% | 29 | $10K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 100 | $10K |
| 81025 | <1% | 35,966 | $10K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,011 | $9K |
| 87070 | <1% | 17,613 | $9K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,114 | $9K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 9,606 | $9K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 99 | $9K |
| 87581 | <1% | 1,016 | $9K | |
| 74019 | <1% | 1,588 | $8K | |
| 84703 | <1% | 15,619 | $8K | |
| 72040 | <1% | 855 | $8K | |
| 93880 | <1% | 105 | $8K | |
| 86140 | <1% | 5,590 | $8K | |
| 29515 | <1% | 41 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 18,094 | $7K |
| 99152 | <1% | 1,992 | $7K | |
| 86901 | <1% | 12,370 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 35,817 | $7K |
| 73060 | <1% | 842 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,693 | $6K |
| 72128 | <1% | 339 | $6K | |
| 43235 | <1% | 18 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,287 | $6K |
| 80061 | Lipid panel | <1% | 2,791 | $6K |
| 96376 | <1% | 5,712 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,347 | $6K |
| 84112 | <1% | 392 | $5K | |
| 78264 | <1% | 12 | $5K | |
| Q4100 | Skin substitute, not otherwise specified | <1% | 202 | $5K |
| 82947 | <1% | 13,595 | $5K | |
| 64447 | <1% | 37 | $5K | |
| 72050 | <1% | 457 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 19,020 | $4K |
| 15853 | <1% | 265 | $4K | |
| 85730 | <1% | 16,289 | $4K | |
| 72170 | <1% | 1,044 | $4K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 655 | $4K |
| 81003 | <1% | 26,286 | $4K | |
| 73562 | <1% | 687 | $4K | |
| 72070 | <1% | 539 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,862 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 23,349 | $4K |
| C1769 | Guide wire | <1% | 2,781 | $3K |
| 82803 | <1% | 4,838 | $3K | |
| 97165 | <1% | 72 | $3K | |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | <1% | 529 | $3K |
| 85014 | <1% | 2,130 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,506 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,271 | $3K |
| 73140 | <1% | 1,666 | $3K | |
| 84520 | <1% | 13,565 | $3K | |
| 84100 | <1% | 4,939 | $3K | |
| 71271 | <1% | 33 | $2K | |
| 87077 | <1% | 5,725 | $2K | |
| 82553 | <1% | 563 | $2K | |
| 76000 | <1% | 1,365 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,889 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 22,046 | $2K |
| 82550 | <1% | 3,658 | $2K | |
| 73221 | <1% | 13 | $2K | |
| 87210 | <1% | 10,476 | $2K | |
| 16020 | <1% | 15 | $2K | |
| 92523 | <1% | 27 | $2K | |
| 99218 | <1% | 118 | $2K | |
| 88341 | <1% | 382 | $2K | |
| 15271 | <1% | 34 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 6,273 | $2K |
| 82731 | <1% | 60 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,212 | $2K |
| 87205 | <1% | 3,957 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 13,177 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,840 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,665 | $2K |
| 85018 | <1% | 2,388 | $2K | |
| 87186 | <1% | 6,982 | $2K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 10,117 | $2K |
| 12013 | <1% | 13 | $2K | |
| 84439 | <1% | 965 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,285 | $1K |
| 82728 | <1% | 502 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,094 | $1K |
| 73700 | <1% | 14 | $1K | |
| 73000 | <1% | 106 | $1K | |
| 85048 | <1% | 2,321 | $1K | |
| 72192 | <1% | 28 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 112 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,152 | $1K |
| 80164 | <1% | 200 | $1K | |
| 87807 | <1% | 7,984 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 8,354 | $1K |
| 71101 | <1% | 264 | $1K | |
| 90686 | <1% | 81 | $1K | |
| A9270 | Non-covered item or service | <1% | 16,805 | $1K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 259 | $1K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 6,326 | $1K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,982 | $1K |
| 82570 | <1% | 991 | $1K | |
| 82010 | <1% | 1,825 | $897.45 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,625 | $868.16 |
| 83540 | <1% | 629 | $856.24 | |
| 83550 | <1% | 344 | $839.66 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 122 | $820.65 |
| 70360 | <1% | 66 | $813.36 | |
| 73070 | <1% | 169 | $753.54 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,046 | $740.18 |
| 85049 | <1% | 2,495 | $735.91 | |
| 83615 | <1% | 862 | $731.51 | |
| J1815 | Injection, insulin, per 5 units | <1% | 6,961 | $677.08 |
| 99153 | Mod sedat endo service >5yrs | <1% | 923 | $646.96 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 143 | $601.44 |
| 73600 | <1% | 174 | $545.92 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,536 | $494.92 |
| 84550 | <1% | 917 | $474.77 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,871 | $469.74 |
| 82248 | <1% | 2,132 | $469.45 | |
| 80069 | <1% | 131 | $467.53 | |
| 74022 | <1% | 134 | $466.81 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,169 | $452.48 |
| 84145 | <1% | 28 | $448.65 | |
| 88342 | <1% | 1,185 | $440.88 | |
| 74220 | <1% | 17 | $430.38 | |
| 80177 | <1% | 69 | $394.90 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,416 | $381.46 |
| 87088 | <1% | 1,926 | $378.55 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,562 | $368.04 |
| 82607 | <1% | 178 | $347.29 | |
| 80074 | <1% | 57 | $321.00 | |
| 84132 | <1% | 1,511 | $320.45 | |
| 73660 | <1% | 83 | $318.14 | |
| 73620 | <1% | 256 | $312.18 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,334 | $292.70 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,191 | $289.33 |
| 85652 | <1% | 417 | $280.54 | |
| 73120 | <1% | 140 | $262.39 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,398 | $257.57 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 159 | $255.80 |
| 87147 | <1% | 1,591 | $242.20 | |
| 85007 | <1% | 191 | $152.78 | |
| J3490 | Unclassified drugs | <1% | 5,456 | $149.36 |
| 73100 | <1% | 39 | $144.85 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,386 | $135.63 |
| 86308 | <1% | 306 | $128.52 | |
| 84156 | <1% | 357 | $123.15 | |
| 85045 | <1% | 506 | $121.54 | |
| 82140 | <1% | 95 | $116.28 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 774 | $108.83 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 476 | $90.54 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 959 | $69.24 |
| 86780 | <1% | 46 | $66.20 | |
| 82746 | <1% | 45 | $55.61 | |
| 87045 | <1% | 51 | $51.63 | |
| 93356 | <1% | 176 | $43.34 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 513 | $40.76 |
| 87340 | <1% | 86 | $37.94 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 3,989 | $35.89 |
| 87046 | <1% | 81 | $34.74 | |
| 88312 | <1% | 134 | $34.00 | |
| C1729 | Catheter, drainage | <1% | 149 | $27.27 |
| 82330 | <1% | 221 | $22.80 | |
| 87899 | <1% | 76 | $21.83 | |
| 36600 | <1% | 47 | $20.55 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 796 | $19.32 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 315 | $15.84 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 108 | $14.69 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 281 | $10.55 |
| 87493 | <1% | 18 | $10.51 | |
| 85520 | <1% | 48 | $9.64 | |
| 87075 | <1% | 97 | $8.64 | |
| S4991 | Nicotine patches, non-legend | <1% | 1,918 | $8.52 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 131 | $5.50 |
| 87176 | <1% | 150 | $4.36 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 226 | $3.96 |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 265 | $1.36 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,069 | $1.19 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 925 | $0.28 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 73 | $0.23 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 42 | $0.23 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 105 | $0.07 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 730 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 367 | $0.00 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 14 | $0.00 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 64 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 222 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 810 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 1,329 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 129 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 464 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 410 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 383 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 239 | $0.00 |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | 0% | 22 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 154 | $0.00 |
| 84295 | 0% | 28 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 201 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 162 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 44 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 33 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 208 | $0.00 |
| 85384 | 0% | 14 | $0.00 | |
| 88302 | 0% | 64 | $0.00 | |
| 15274 | 0% | 37 | $0.00 | |
| C1771 | Repair device, urinary, incontinence, with sling graft | 0% | 20 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 29 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 14 | $0.00 |
| 15273 | 0% | 17 | $0.00 | |
| 86738 | 0% | 39 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 325 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 12 | $0.00 |
| C9363 | Skin substitute, integra meshed bilayer wound matrix, per square centimeter | 0% | 16 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 61 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 60 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 163 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 26 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 22 | $0.00 |
| 94644 | 0% | 12 | $0.00 | |
| 15003 | 0% | 71 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 24 | $0.00 |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 14 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFOSNESS, DUSTIN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Chippenham & Johnston-Willis Hospitals, INC. | Chesterfield, VA | $2.80M |
| Chippenham & Johnston-Willis Hospitals, INC. | Richmond, VA | $285K |
| Chippenham & Johnston-Willis Hospitals INC | Richmond, VA | $216.11 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.